The largest database of trusted experimental protocols
> Physiology > Molecular Function > Protein Glycosylation

Protein Glycosylation

Protein Glycosylation is the enzymatic process of adding glycan (sugar) chains to proteins, which occurs in the endoplasmic reticulum and Golgi apparatus of eukaryotic cells.
This post-translational modification can alter a protein's stability, solubility, folding, trafficking, and biological activity.
Glycosylation patterns may also serve as biomarkers for various diseases.
Accurate characterization of glycan structures is crucial for understanding protein function and developing therapeutic glycoproteins.
PubCompare.ai is a powerful tool that can optimize protein glycosylation research by helping scientists easily locate relevant protocols and leverage AI-driven comparisons to identify the best methods and products, enhancing reproducibility and accuacy in glycosylation studies.

Most cited protocols related to «Protein Glycosylation»

The numbered positions of annotated residues in the Swiss-Prot sequence often do not align to the same numbered positions of the sequence from the PDB structure. Therefore, a mapping of positions between the Swiss-Prot sequence and the PDB sequence must be obtained. We use a variation of the Needleman and Wunsch algorithm to identify if a sequence of a PDB structure can be found to match the sequence containing annotated residues from the Swiss-Prot database.
Specifically, every Swiss-Prot sequence containing one or more annotated residues and a link to a PDB structure was aligned to the corresponding sequence of the PDB structure. Standard annotations of Swiss-Prot used include post-translational modifications (MOD_RES), covalent binding of a lipid moiety (LIPID), glycosylation sites (CARBOHYD), post-translational formed amino acid bonds (CROSSLNK), metal binding sites (METAL), chemical group binding sites (BINDING), calcium binding regions (CA_BIND), DNA binding regions (DNA_BIND), nucleotide phosphate binding regions (NP_BIND), zinc finger regions (ZN_FING), enzyme activity amino acids (ACT_SITE) and any interesting single amino acid site (SITE). To ensure that the mapping is accurate, only alignments of two sequences with a sequence identity greater than ninety five percent were used. The annotated positions from Swiss-Prot are then transferred onto the PDB sequence, as long as the position is not aligned to a gap.
Publication 2006
Amino Acids Binding Sites Calcium enzyme activity Lipid A Lipids Metals Nucleotides Phosphates Protein Biosynthesis Protein Glycosylation Sequence Alignment Zinc Fingers
Proteins that could accommodate backbone grafting of the V1/V2 stub from HIV-1 gp120 were identified using the Multigraft Match algorithm48 (link) implemented in Rosetta. Potential V1/V2 scaffolds were examined manually and, if necessary, optimizations were made to accommodate full-length V1/V2 loops (residues 126–196) or to alter scaffold properties (for example, mutating the intrinsic immunoglobulin affinity of 1FD6; ref. 49 (link)). For each V1/V2 scaffold, protein-A-purified PG9, altered to remove light-chain glycosylation and to introduce an HRV3C cleavage site in the hinge, was bound to Protein A Plus agarose, and the V1/V2 scaffold added. After washing away unbound scaffold, HRV3C protease was added to elute the PG9 Fab–V1/V2 scaffold complex. Complexes of PG9 Fab bound to 1FD6-CAP45 or 1FD6-ZM109 crystallized in similar conditions50 (link) (8–17% (w/v) PEG 3350, 5–10% (v/v) 2-methyl-2,4-pentanediol, 0.2 M lithium sulphate, 0.1 M imidazole pH 6.5). Crystals were cryoprotected with 15% (v/v) 2R,3R-butanediol, diffraction data were collected to 2.19 and 1.80 Å for PG9–1FD6-CAP45 and PG9–1FD6-ZM109, respectively, and structures solved by molecular replacement.
Publication 2011
Antibody Affinity Butylene Glycols Cytokinesis HIV Envelope Protein gp120 imidazole lithium sulfate Peptide Hydrolases polyethylene glycol 3350 Protein Glycosylation Proteins Sepharose Staphylococcal Protein A TNFSF14 protein, human Vertebral Column
The sequences of all the PPRs were identified with reference to the 11,938 sequences of Orthohepevirus A (including 338 complete HEV genomes) available in the Virus Pathogen Resource (VIPR) database.5 Selected sequences were systematically searched to identify insertions so that they could be used, together with those identified by PacBio sequencing, for further analysis. The compositions of HEV PPR insertions/duplications were determined and their post-translational modifications predicted by analyzing a range of parameters. Potential ubiquitination sites were identified using the BDM-PUB server6 with a threshold of >0.3 average potential score. Potential phosphorylation sites were identified using the NetPhos 3.1 server7 with a threshold of >0.5 average potential score. Potential acetylation sites were identified using the Prediction of Acetylation on Internal Lysines (PAIL) server8 with a threshold of >0.2 average potential score. Potential N-linked glycosylation sites were identified using the NetNGlyc 1.0 server9 with a threshold of >0.5 average potential score. Potential methylation sites were identified using the BPB-PPMS server10 with a threshold of >0.5 average potential score. Nuclear export signal (NES) sites were identified using the Wregex server11 with parameters NES/CRM1 and Relaxed. Nuclear localization signal (NLS) sites were identified using SeqNLS12 with a 0.86 cut-off. The amino acid composition (proportions of amino acids), physico-chemical composition, and net load were analyzed with R. Principal component analysis (PCA) is a mathematical algorithm that reduces the dimensionality of the data while retaining most of the variation in a data set. PCA allows to identify new variables, the principal components, which are linear combinations of the original variables (Ringner, 2008 (link)). PCA was done (excluding the amino acid composition due to redundancy with physico-chemical properties) to summarize and visualize the information on the variables in our data set (Abdi and Williams, 2010 (link)); each variable was then studied independently. An in-house R-pipeline based on the amino acid sequences and the results of each analysis was used to generate bar plots for amino acid composition. The amino acid compositions were assigned to one of two categories: sequences with insertions/duplications (including insertions of human genome and HEV genome duplications) and sequences without insertions/duplications. The other parameters were assigned to one of three categories: sequences with insertions, those with duplications, and sequences without insertion/duplication.
Publication 2020
Acetylation Amino Acids Amino Acid Sequence chemical composition chemical properties DNA Insertion Elements Genome Genome, Human Insertion Mutation Lysine Methylation Nuclear Export Signals Nuclear Localization Signals Pathogenicity Phosphorylation Protein Glycosylation Sequence Insertion Ubiquitination Virus
The neutralization panel data (IC50 and IC80 values for specific monoclonal antibodies and pseudotyped viruses) were collected from 49 published neutralization studies, mostly from tables in PDF format provided in the supplemental materials. The viral data was collected from Los Alamos HIV Database and in some cases personal communication with the authors, and required careful consideration and systematization to resolve sequence name ambiguities between different laboratories. Antibody sequences were downloaded from GenBank, and links to the structures in Protein Data Bank are provided. Standard statistics are applied to tally and analyze neutralization results. Specifically, antibody associations with viral mutations are evaluated by Fisher's exact test, counting the number of antibody-resistant or antibody-sensitive viruses (above or below threshold of detection) and the presence or absence of specific amino acids or N-glycosylation motif in the viral sequence alignment position (12 (link)).
Publication 2015
Amino Acids Antibodies Antibodies, Viral Monoclonal Antibodies Mutation Protein Glycosylation Pseudotyped Viruses Sequence Alignment Virus
The GABAAR-β3cryst structure was solved by molecular replacement using the C. elegans glutamate-gated chloride channel α (GluClα66 (link), PDB accession code 3RHW) as a search model in Phaser67 (link). An initial round of automated model building, structure refinement and density modification was performed using Phenix AutoBuild68 (link) followed by iterative steps of manual model building in Coot69 (link) and refinement in Buster70 . During the refinement/building process it became clear that the N-terminal region of one GABAAR-β3cryst monomer (chain A) adopted a distinct, well-ordered, conformation because of its involvement in crystal contacts. As a result, the strict five-fold non-crystallographic symmetry (NCS) restraints strategy was replaced at later stages by a local structural similarity restraints NCS approach, to allow pruning of genuine differences among matching chains from the NCS relation71 (link). The final model contains one GABAAR-β3cryst homopentamer per asymmetric unit. The complete polypeptide chains could be built, except the C-terminal TETSQVAPA purification tag and the first nine N-terminal residues (QSVNDPGNM) in chains B, C, D and E. Furthermore, clear electron density is visible for benzamidine molecules, one of which occupies every orthosteric ligand binding site, as well as 11 out of the 15 N-linked glycosylation sites, the remaining four being located in the N-terminal disordered regions of chains B-E. Glycans attached to Asn 149 in each chain were protected from endoglycosidase F1 cleavage due to extensive interactions with the protein core, underlying their important structural role. Stereochemical properties of the model were assessed in Coot69 (link) and Molprobity72 (link). Protein geometry analysis revealed no Ramachandran outliers, with 96.98% residues in favoured regions and 3.02% residues in allowed regions. Molprobity clash score after adding hydrogens is 5.74 (100th percentile) and the overall Molprobity score is 1.85 (100th percentile).
Sequence and structural alignments were performed in ClustalW73 (link) and SHP74 (link), respectively. Protein interfaces were analysed using the PDBePISA web server at the European Bioinformatics Institute (http://www.ebi.ac.uk/pdbe/prot_int/pistart.html)75 (link) and residue conservation was mapped onto the crystal structure using ProtSkin76 (link). Electrostatic surface potential calculations were performed using the APBS Tools plug-in in PyMOL77 (link) and pore/tunnel dimensions were analysed using the Caver 3.0 software for a probe radius of 1.4 Å78 (link). Structural figures were prepared with the PyMOL Molecular Graphics System, Version 1.6, Schrödinger, LLC.
Publication 2014
benzamidine Binding Sites Caenorhabditis elegans Crystallography Cytokinesis Electrons Electrostatics Endoglycosidases Europeans glutamate-gated chloride channel Hydrogen Ligands Polypeptides Polysaccharides Protein Glycosylation Proteins Radius

Most recents protocols related to «Protein Glycosylation»

Example 1

a. Materials and Methods

i. Vector Construction

1. Virus-Like Particle

As most broadly neutralizing HPV antibodies are derived from the highly conserved N-terminal region of L2, amino acids 14-122 of HPV16 L2 were used to create HBc VLPs. L2 with flanking linker regions was inserted into the tip of the a-helical spike of an HBc gene copy which was fused to another copy of HBc lacking the L2 insert. This arrangement allows the formation of HBc dimers that contain only a single copy of L2, increasing VLP stability (Peyret et al. 2015). This heterodimer is referred to as HBche-L2. A dicot plant-optimized HPV16 L2 coding sequence was designed based upon the sequence of GenBank Accession No. CAC51368.1 and synthesized in vitro using synthetic oligonucleotides by the method described (Stemmer et al., 1995). The plant-optimized L2 nucleotide sequence encoding residues 1-473 is posted at GenBank Accession No. KC330735. PCR end-tailoring was used to insert Xbal and SpeI sites flanking the L2 aa 14-122 using primers L2-14-Xba-F (SEQ ID NO. 1: CGTCTAGAGTCCGCAACCCAACTTTACAAG) and L2-122-Spe-R (SEQ ID NO. 2: G GGACTAGTTGGGGCACCAGCATC). The SpeI site was fused to a sequence encoding a 6His tag, and the resulting fusion was cloned into a geminiviral replicon vector (Diamos, 2016) to produce pBYe3R2K2Mc-L2(14-122)6H.

The HBche heterodimer VLP system was adapted from Peyret et al (2015). Using the plant optimized HBc gene (Huang et al., 2009), inventors constructed a DNA sequence encoding a dimer comprising HBc aa 1-149, a linker (G2S)5G (SEQ ID NO. 39), HBc aa 1-77, a linker GT(G4S)2 (SEQ ID NO. 40), HPV-16 L2 aa 14-122, a linker (GGS)2GSSGGSGG (SEQ ID NO. 41), and HBc aa 78-176. The dimer sequence was generated using multiple PCR steps including overlap extensions and insertion of BamHI and SpeI restriction sites flanking the L2 aa 14-122, using primers L2-14-Bam-F (SEQ ID NO. 3: CAGGATCCGCAACC CAACTTTACAAGAC) and L2-122-Spe-R (SEQ ID NO. 2). The HBche-L2 coding sequence was inserted into a geminiviral replicon binary vector pBYR2eK2M (FIG. 3), which includes the following elements: CaMV 35S promoter with duplicated enhancer (Huang et al., 2009), 5′ UTR of N. benthamiana psaK2 gene (Diamos et al., 2016), intron-containing 3′ UTR and terminator of tobacco extensin (Rosenthal et al, 2018), CaMV 35S 3′ terminator (Rosenthal et al, 2018), and Rb7 matrix attachment region (Diamos et al., 2016).

2. Recombinant Immune Complex

The recombinant immune complex (RIC) vector was adapted from Kim et al., (2015). The HPV-16 L2 (aa 14-122) segment was inserted into the BamHI and SpeI sites of the gene encoding humanized mAb 6D8 heavy chain, resulting in 6D8 epitope-tagged L2. The heavy chain fusion was inserted into an expression cassette linked to a 6D8 kappa chain expression cassette, all inserted into a geminiviral replicon binary vector (FIG. 3, RIC vector). Both cassettes contain CaMV 35S promoter with duplicated enhancer (Huang et al., 2009), 5′ UTR of N. benthamiana psaK2 gene (Diamos et al., 2016), intron-containing 3′ UTR and terminator of tobacco extensin (Rosenthal et al, 2018), and Rb7 matrix attachment region (Diamos et al., 2016).

ii. Agroinfiltration of Nicotiana benthamiana Leaves

Binary vectors were separately introduced into Agrobacterium tumefaciens EHA105 by electroporation. The resulting strains were verified by restriction digestion or PCR, grown overnight at 30° C., and used to infiltrate leaves of 5- to 6-week-old N. benthamiana maintained at 23-25° C. Briefly, the bacteria were pelleted by centrifugation for 5 minutes at 5,000 g and then resuspended in infiltration buffer (10 mM 2-(N-morpholino)ethanesulfonic acid (MES), pH 5.5 and 10 mM MgSO4) to OD600=0.2, unless otherwise described. The resulting bacterial suspensions were injected by using a syringe without needle into leaves through a small puncture (Huang et al. 2004). Plant tissue was harvested after 5 DPI, or as stated for each experiment. Leaves producing GFP were photographed under UV illumination generated by a B-100AP lamp (UVP, Upland, CA).

iii. Protein Extraction

Total protein extract was obtained by homogenizing agroinfiltrated leaf samples with 1:5 (w:v) ice cold extraction buffer (25 mM sodium phosphate, pH 7.4, 100 mM NaCl, 1 mM EDTA, 0.1% Triton X-100, 10 mg/mL sodium ascorbate, 0.3 mg/mL PMSF) using a Bullet Blender machine (Next Advance, Averill Park, NY) following the manufacturer's instruction. To enhance solubility, homogenized tissue was rotated at room temperature or 4° C. for 30 minutes. The crude plant extract was clarified by centrifugation at 13,000 g for 10 minutes at 4° C. Necrotic leaf tissue has reduced water weight, which can lead to inaccurate measurements based on leaf mass. Therefore, extracts were normalized based on total protein content by Bradford protein assay kit (Bio-Rad) with bovine serum albumin as standard.

iv. SDS-PAGE and Western Blot

Clarified plant protein extract was mixed with sample buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 0.02% bromophenol blue) and separated on 4-15% polyacrylamide gels (Bio-Rad). For reducing conditions, 0.5M DTT was added, and the samples were boiled for 10 minutes prior to loading. Polyacrylamide gels were either transferred to a PVDF membrane or stained with Coomassie stain (Bio-Rad) following the manufacturer's instructions. For L2 detection, the protein transferred membranes were blocked with 5% dry milk in PBST (PBS with 0.05% tween-20) overnight at 4° C. and probed with polyclonal rabbit anti-L2 diluted 1:5000 in 1% PBSTM, followed by goat anti-rabbit horseradish peroxidase conjugate (Sigma). Bound antibody was detected with ECL reagent (Amersham).

v. Immunization of Mice and Sample Collection

All animals were handled in accordance to the Animal Welfare Act and Arizona State University IACUC. Female BALB/C mice, 6-8 weeks old, were immunized subcutaneously with purified plant-expressed L2 (14-122), HBche-L2 VLP, L2 RIC, or PBS mixed 1:1 with Imject® Alum (Thermo Scientific, Rockford, IL). In all treatment groups, the total weight of antigen was set to deliver an equivalent 5 μg of L2. Doses were given on days 0, 21, and 42. Serum collection was done as described (Santi et al. 2008) by submandibular bleed on days 0, 21, 42, and 63.

vi. Antibody Measurements

Mouse antibody titers were measured by ELISA. Bacterially-expressed L2 (amino acids 11-128) was bound to 96-well high-binding polystyrene plates (Corning), and the plates were blocked with 5% nonfat dry milk in PBST. After washing the wells with PBST (PBS with 0.05% Tween 20), the diluted mouse sera were added and incubated. Mouse antibodies were detected by incubation with polyclonal goat anti-mouse IgG-horseradish peroxidase conjugate (Sigma). The plate was developed with TMB substrate (Pierce) and the absorbance was read at 450 nm. Endpoint titers were taken as the reciprocal of the lowest dilution which produced an OD450 reading twice the background. IgG1 and IgG2a antibodies were measured with goat-anti mouse IgG1 or IgG2a horseradish peroxidase conjugate.

vii. Electron Microscopy

Purified samples of HBche or HBche-L2 were initially incubated on 75/300 mesh grids coated with formvar. Following incubation, samples were briefly washed twice with deionized water then negatively stained with 2% aqueous uranyl acetate. Transmission electron microscopy was performed with a Phillips CM-12 microscope, and images were acquired with a Gatan model 791 CCD camera.

viii. Statistical Analysis

The significance of vaccine treatments and virus neutralization was measured by non-parametric Mann-Whitney test using GraphPad prism software. Two stars (**) indicates p values <0.05. Three stars (***) indicates p values <0.001.

b. Design and Expression of HBc VLPs and RIC Displaying HPV16 L2

BeYDV plant expression vectors (FIG. 3) expressing either the target VLP HBche-L2, or L2 and HBche alone as controls, were agroinfiltrated into the leaves of N. benthamiana and analyzed for VLP production. After 4-5 days post infiltration (DPI), leaves displayed only minor signs of tissue necrosis, indicating that the VLP was well-tolerated by the plants (FIG. 4A). Leaf extracts analyzed by reducing SDS-PAGE showed an abundant band near the predicted size of 51 kDa for HBche-L2, just above the large subunit of rubisco (RbcL). HBche was detected around the predicted size of 38 kDa (FIG. 4B). Western blot probed with anti-L2 polyclonal serum detected a band for HBche-L2 at ˜51 kDa (FIG. 4B). These results indicate that this plant system is capable of producing high levels of L2-containing HBc VLP.

To express L2-containing MC, amino acids 14-122 of HPV16 L2 were fused with linker to the C-terminus of the 6D8 antibody heavy chain and tagged with the 6D8 epitope (Kim et al. 2015). A BeYDV vector (FIG. 3) expressing both the L2-fused 6D8 heavy chain and the light chain was agroinfiltrated into leaves of N. benthamiana and analyzed for RIC production. To create more homogenous human-type glycosylation, which has been shown to improve antibody Fc receptor binding in vivo, transgenic plants silenced for xylosyltransferase and fucosyltransferase were employed (Castilho and Steinkellner 2012). By western blot, high molecular weight bands >150 kDa suggestive of RIC formation were observed (FIG. 4C). Expression of soluble L2 RIC was lower than HBche-L2 due to relatively poor solubility of the RIC (FIG. 4C).

After rigorous genetic optimization, the N. benthamiana system is capable of producing very high levels of recombinant protein, up to 30-50% of the total soluble plant protein, in 4-5 days (Diamos et al. 2016). Using this system, we produced and purified milligram quantities of fully assembled and potently immunogenic HBc VLPs displaying HPV L2 through a simple one-step purification process (FIGS. 4A-4C and 6).

c. Purification and Characterization of HBche-L2 and L2 RIC

To assess the assembly of HBc-L2 VLP, clarified plant extracts containing either HBche-L2 or HBche were analyzed by sucrose gradient sedimentation. HBche-L2 sedimented largely with HBche, which is known to form VLP, though a small increase in density was observed with HBche-L2, perhaps due to the incorporation of L2 into the virus particle (FIG. 5A). To demonstrate particle formation, sucrose fractions were examined by electron microscopy. Both HBche and HBche-L2 formed ˜30 nm particles, although the appearance of HBche-L2 VLP suggested slightly larger, fuller particles (FIGS. 5C and 5D). As most plant proteins do not sediment with VLP, pooling peak sucrose fractions resulted in >95% pure HBche-L2 (FIG. 5B), yielding sufficient antigen (>3 mg) for vaccination from a single plant leaf.

L2 RIC was purified from plant tissue by protein G affinity chromatography. By SDS-PAGE, an appropriately sized band was visible >150 kDa that was highly pure (FIG. 5B). Western blot confirmed the presence of L2 in this band, indicating proper RIC formation (FIG. 5B). L2 RIC bound to human complement C1q receptor with substantially higher affinity compared to free human IgG standard, suggesting proper immune complex formation (FIG. 5E).

d. Mouse Immunization with HBche-L2 and L2 RIC

Groups of Balb/c mice (n=8) were immunized, using alum as adjuvant, with three doses each of 5 μg L2 delivered as either L2 alone, HBche-L2 VLP, L2 RIC, or a combination of half VLP and half RIC. VLP and RIC, alone or combined, greatly enhanced antibody titers compared to L2 alone by more than an order of magnitude at all time points tested (FIG. 6). After one or two doses, the combined VLP/RIC treatment group outperformed both the VLP or RIC groups, reaching mean endpoint titers of >200,000, which represent a 700-fold increase over immunization with L2 alone (FIG. 6). After the third dose, both the VLP and combined VLP/RIC groups reached endpoint titers >1,300,000, a 2-fold increase over the RIC alone group. To determine the antibody subtypes produced by each treatment group, sera were assayed for L2-binding IgG1 and IgG2a. All four groups produced predominately IgG1 (FIG. 7, note dilutions). However, RIC and especially VLP-containing groups had an elevated ratio of IgG2a:IgG1 (>3-fold) compared to L2 alone (FIG. 7).

In vitro neutralization of HPV16 pseudovirions showed that the VLP and RIC groups greatly enhanced neutralization compared to L2 alone (FIG. 5, p<0.001). Additionally, VLP and RIC combined further enhanced neutralization activity ($5-fold, p<0.05) compared to either antigen alone, supporting the strong synergistic effect of delivering L2 by both platforms simultaneously.

In this study, by displaying amino acids 11-128 on the surface of plant-produced HBc VLPs, L2 antibody titers as high as those seen with L1 vaccines were generated (FIG. 6). Mice immunized with L2 alone had highly variable antibody titers, with titers spanning two orders of magnitude. By contrast, the other groups had much more homogenous antibody responses, especially the VLP-containing groups, which had no animals below an endpoint titer of 1:1,000,000 (FIG. 6). These results underscore the potential of HBc VLP and RIC to provide consistently potent immune responses against L2. Moreover, significant synergy of VLP and RIC systems was observed when the systems were delivered together, after one or two doses (FIG. 6). Since equivalent amounts of L2 were delivered with each dose, the enhanced antibody titer did not result from higher L2 doses. Rather, these data suggest that higher L2-specific antibody production may be due to augmented stimulation of L2-specific B cells by T-helper cells that were primed by RIC-induced antigen presenting cells. Although treatment with VLP and RIC alone reached similar endpoint titers as the combined VLP/RIC group after 3 doses, virus neutralization was substantially higher (>5-fold) in the combined group (FIG. 8). Together, these data indicate unique synergy exists when VLP and RIC are delivered together. Inventors have observed similarly significant synergistic enhancement of immunogenicity for a variety of other antigens.

Mice immunized with L2 alone had highly variable antibody titers, with titers spanning two orders of magnitude. By contrast, the VLP and VLP/RIC groups had much more homogenous antibody responses, with no animals below an endpoint titer of 1:1,000,000 (FIG. 6). These results underscore the potential of HBc VLP and RIC to provide consistently potent immune responses against L2.

Fc gamma receptors are present on immune cells and strongly impact antibody effector functions such as antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity (Jefferis 2009). In mice, these interactions are controlled in part by IgG subtypes. IgG1 is associated with a Th2 response and has limited effector functions. By contrast, IgG2a is associated with a Th1 response and more strongly binds complement components (Neuberger and Raj ewsky 1981) and Fc receptors (Radaev 2002), enhancing effector functions and opsonophagocytosis by macrophages (Takai et al. 1994). Immunization with L2 alone was found to produce low levels of IgG2a, however immunization with RIC and VLP produced significant increases in IgG2a titers. VLP-containing groups in particular showed a 3-fold increase in the ratio of IgG2a to IgG1 antibodies (FIG. 7). Importantly, production of IgG2a is associated with successful clearance of a plethora of viral pathogens (Coutelier et al. 1988; Gerhard et al. 1997; Wilson et al. 2000; Markine-Goriaynoff and Coutelier 2002).

The glycosylation state of the Fc receptor also plays an important role in antibody function. Advances in glycoengineering have led to the development of transgenic plants with silenced fucosyl- and xylosyl-transferase genes capable of producing recombinant proteins with authentic human N-glycosylation (Strasser et al. 2008). Antibodies produced in this manner have more homogenous glycoforms, resulting in improved interaction with Fc gamma and complement receptors compared to the otherwise identical antibodies produced in mammalian cell culture systems (Zeitlin et al. 2011; Hiatt et al. 2014; Strasser et al. 2014; Marusic et al. 2017). As the known mechanisms by which RIC vaccines increase immunogenicity of an antigen depend in part on Fc and complement receptor binding, HPV L2 RIC were produced in transgenic plants with silenced fucosyl- and xylosyl-transferase. Consistent with these data, we found that L2 RIC strongly enhanced the immunogenicity of L2 (FIG. 6). However, yield suffered from insolubility of the RIC (FIG. 4C). We found that the 11-128 segment of L2 expresses very poorly on its own in plants and may be a contributing factor to poor L2 RIC yield. Importantly, we have produced very high yields of RIC with different antigen fusions. Thus, in some aspects, antibody fusion with a shorter segment of L2 could substantially improve the yield of L2 RIC.

e. Neutralization of HPV Pseudovirions

Neutralization of papilloma pseudoviruses (HPV 16, 18, and 58) with sera from mice immunized IP with HBc-L2 VLP and L2(11-128) showed neutralization of HPV 16 at titers of 400-1600 and 200-800, respectively (Table 1). More mice IP-immunized with HBc-L2 VLP had antisera that cross-neutralized HPV 18 and HPV 58 pseudoviruses, compared with mice immunized with L2(11-128). Anti-HBc-L2 VLP sera neutralized HPV 18 at titers of 400 and HPV 58 at titers ranging from 400-800 (Table 1), while anti-L2(11-128) sera neutralized HPV 18 at a titer of 200 and HPV 58 at a titer of 400 (Table 1). None of the sera from intranasal-immunized mice demonstrated neutralizing activity, consistent with lower anti-L2 titers for intranasal than for intraperitoneal immunized mice.

TABLE 1
L2-specific serum IgG and pseudovirus neutralization
titers from IP immunized mice
Neutralization of Pseudoviruses
ImmunogenSerum IgGHPV 16HPV 18HPV 58
HBc-L2>50,000 400
~70,0001600400400
>80,0001600400800
L2 (11-128)~8000 200
~12,000 400
~50,000 800200400

Patent 2024
3' Untranslated Regions 5' Untranslated Regions AA 149 Agrobacterium tumefaciens aluminum potassium sulfate aluminum sulfate Amino Acids Animals Animals, Transgenic Antibodies Antibody Formation Antigen-Presenting Cells Antigens B-Lymphocytes Bacteria Bromphenol Blue Buffers Cell Culture Techniques Cells Centrifugation Chromatography, Affinity Cloning Vectors Cold Temperature Combined Modality Therapy complement 1q receptor Complement Receptor Complex, Immune Complex Extracts Cytotoxicities, Antibody-Dependent Cell Cytotoxin Digestion DNA, A-Form DNA Sequence Edetic Acid Electron Microscopy Electroporation Enzyme-Linked Immunosorbent Assay Epitopes ethane sulfonate Fc Receptor Females Formvar Fucosyltransferase G-substrate Gamma Rays Genes Genes, vif Glycerin Goat Helix (Snails) Helper-Inducer T-Lymphocyte Homo sapiens Homozygote Horseradish Peroxidase Human papillomavirus 16 Human papillomavirus 18 Human Papilloma Virus Vaccine IGG-horseradish peroxidase IgG1 IgG2A Immune Sera Immunoglobulin Heavy Chains Immunoglobulins Immunologic Factors Institutional Animal Care and Use Committees Introns Inventors L2 protein, Human papillomavirus type 16 Light Macrophage Mammals Matrix Attachment Regions Mice, Inbred BALB C Microscopy Milk, Cow's Morpholinos Mus Necrosis Needles Nicotiana Oligonucleotide Primers Oligonucleotides Open Reading Frames Opsonophagocytosis Papilloma Pathogenicity Plant Development Plant Extracts Plant Leaves Plant Proteins Plants Plants, Transgenic polyacrylamide gels Polystyrenes polyvinylidene fluoride prisma Protein Glycosylation Proteins Punctures Rabbits Receptors, IgG Recombinant Proteins Replicon Reproduction Response, Immune Ribulose-Bisphosphate Carboxylase Large Subunit Satellite Viruses SDS-PAGE Serum Serum Albumin, Bovine Sodium Ascorbate Sodium Chloride sodium phosphate Specimen Collection Stars, Celestial Strains Sucrose Sulfate, Magnesium Syringes System, Immune Technique, Dilution Tissue, Membrane Tissues Transferase Transmission Electron Microscopy Triton X-100 Tromethamine Tween 20 Ultraviolet Rays uranyl acetate Vaccination Vaccines Vaccines, Recombinant Virion Viroids Virus Vision Western Blotting xylosyltransferase
Not available on PMC !

Example 2

SuperM5 was stored in different conditions at −80° C., −4° C., 20° C. and at room temperature. Strains were stored as frozen glycerol stocks and as stab cultures. Different cultures were stored and thawed for different experiments and for shipping to collaborators for testing. In all cases the strains recovered, plated and cultured similar to the parent Pichia pastoris GS115 strain and grew in both complex and defined media similar to the parent strains. The SuperM5 strains transformed similarly as the parent strain and proteins were expressed with the mannose-5 glycosylation as the predominate glycoform, or the only glycoform. Strains have been repeatedly stored and regrown to establish robustness of the SuperM5 strains.

Patent 2024
Freezing Glycerin Komagataella pastoris Mannose Parent Protein Glycosylation Proteins Strains
96-well plates were coated with recombinant human IgG1.Fc (A42561; Invitrogen) or human LRP-1 Cluster II Fc Chimera Protein covering ∼10% of the full-length Lpr1 protein sequence, including 3 N-glycosylation sites (#2368-L2-050; R&D Systems) at 0.5 μg in 100 μl PBS, incubated at 4°C overnight, and blocked with 50 mg/ml BSA for 90 min at 30°C. Serial concentrations ranging from 0.1 to 3.2 μg of recombinant human GALECTIN-3 (#774408; Biolegend), and test agents were added in a total volume of 50 μl and then incubated for 4 h at 30°C. Wells were washed, fixed with 2% PFA in PBS for 15 min at room temperature, washed, and incubated with rat anti-mouse monoclonal galectin-3 antibody (#125401; Biolegend; clone M3/38, epitopes mapped within the N-terminal region) for 30 min on ice. After washing, wells were incubated with AF488-conjugated donkey anti-rat secondary antibody (A-21208; Invitrogen Molecular Probes) for 30 min on ice. After washing, fluorescence was determined using a SpectraMax L (Molecular Devices) plate reader (excitation 485, emission 538) to quantify galectin-3–Lrp1 binding.
Publication 2023
Amino Acid Sequence Antibodies, Anti-Idiotypic Chimera Clone Cells Epitopes Equus asinus Fluorescence Galectin 3 Homo sapiens IgG1 LGALS3 protein, human Medical Devices Mice, House Molecular Probes Monoclonal Antibodies NR4A2 protein, human Protein Glycosylation
The raw files were
converted into mzXML files and searched against the human (Homo sapiens) proteome database from UniProt using
the SEQUEST algorithm (version 28).16 (link) The
following parameters were used for the search of glycopeptides: 20
ppm precursor mass tolerance; 0.025 Da fragment ion mass tolerance;
up to two missed cleavages; up to three modifications on each peptide;
variable modification on serine, threonine, and cysteine (+528.2859
Da) for TMT-labeled O-GlcNAc; and fixed modifications
including oxidation of methionine (+15.9949 Da) and TMT modification
on lysine and the peptide N-terminus (+229.1629 Da). For glycopeptide
identifications, the data quality was evaluated and well-controlled
using linear discriminant analysis (LDA).17 (link) The parameters used include XCorr, ΔCorr, missed cleavages,
adjusted ppm, peptide length, and charge state. Peptides with fewer
than seven amino acid residues were discarded. Finally, the false
discovery rates (FDRs) of glycopeptides were controlled to <1%.
ModScore was used to determine the confidence of the glycosylation
site localization.18 (link) Sites with ModScore
>13 (P < 0.05) were considered as confidently
localized, and only the confidently localized sites were used for
site-specific analysis.19 (link),20 (link) To remove S-glycosylation sites, we have applied very stringent criteria to
make sure that only confidently identified O-glycosylation
sites were included in the data set. The detailed filtering steps
are the same with our previous publications.6 (link),20 (link) The
isotopic correction parameters provided by Thermo were used to calibrate
the TMT reporter ion intensities before data analysis. For the two
TMT channels for the samples of co-translational O-GlcNAcylation, the S/N ratio in
at least one sample has to be >5 for confident annotation of co-translational O-GlcNAcylated peptides.
Publication 2023
Amino Acids Cysteine Cytokinesis Glycopeptides Homo sapiens Immune Tolerance Lysine Methionine Peptides Protein Biosynthesis Protein Glycosylation Proteome Self Confidence Serine Threonine
The epitope regions of CR3022 and S309 were determined using the published structural data in protein data bank (PDB (40 (link)–43 (link))) for the antibody complexed with SARS-CoV-2 viz. PDB id. 6W41 for CR3022 (41 (link)) and PDB id. 6WPS for S309 (42 (link)). All the amino acids in antigens that are within 5Å contact of amino acids of antibodies were considered as epitope residues. The position of the glycosylation site was determined by in-silico mutation of triplets of amino acids in the epitopes to glycosylation sequon – N-X-T (44 (link)) using the FoldX algorithm (43 (link)). Briefly, residues succeeding N-X motif, where X can be any amino acid except Pro, were mutated to either Threonine or Serine or residues preceding X-T, where X can be any amino acid except Pro, were mutated to Asn to generate novel N-X-T/S motifs. The mutations with the least energy cost, as calculated by the Build module of FoldX, were selected for designing M7 and M8.
Publication 2023
Amino Acids Antibodies Antigens CR3022 Epitopes Immunoglobulins Mutation Protein Glycosylation SARS-CoV-2 Serine Threonine Triplets

Top products related to «Protein Glycosylation»

Sourced in United States, United Kingdom, Germany, Japan, Canada, France, China, Morocco, Italy
PNGase F is an enzyme that cleaves the bond between the asparagine residue and the N-acetylglucosamine residue in N-linked glycoproteins. It is commonly used in the analysis and characterization of glycoproteins.
Sourced in United States, United Kingdom, Germany, Canada, Switzerland, France
Endo H is a glycosidase enzyme that cleaves the chitobiose core of high mannose and some hybrid-type oligosaccharides from N-linked glycoproteins. It removes the N-linked glycans from glycoproteins, allowing the study of the effects of glycosylation on protein structure and function.
Sourced in United States, Germany, Sao Tome and Principe, Macao, United Kingdom, China, Canada, France, Ireland, Poland
Tunicamycin is a naturally occurring antibiotic compound that inhibits the synthesis of N-linked glycoproteins. It is commonly used as a laboratory tool for research purposes.
Sourced in United States, Germany, China
PNGase F is an enzyme that cleaves the linkage between the asparagine residue and the first N-acetylglucosamine of N-glycans. It is a commonly used tool in glycobiology research for the removal of N-linked glycans from glycoproteins.
Sourced in United States, Japan
O-glycosidase is an enzyme that catalyzes the removal of O-linked glycosidic bonds from glycoproteins. It is used in biochemical research and analysis for the study of protein glycosylation patterns.
Sourced in United States
The Pierce Glycoprotein Staining Kit is a laboratory product designed to detect and visualize glycoproteins in gel electrophoresis applications. It provides a simple, sensitive, and reliable method for staining glycoproteins in polyacrylamide gels.
Sourced in United States, Germany, United Kingdom, France, Italy, New Zealand
The GeneArt is a laboratory equipment product designed for genetic engineering and molecular biology applications. It provides tools and functionalities for DNA synthesis, assembly, and modification. The core function of the GeneArt is to enable researchers and scientists to create and manipulate genetic constructs for various experimental and research purposes.
Sourced in United States, China, Germany, United Kingdom, Canada, Japan, France, Italy, Switzerland, Australia, Spain, Belgium, Denmark, Singapore, India, Netherlands, Sweden, New Zealand, Portugal, Poland, Israel, Lithuania, Hong Kong, Argentina, Ireland, Austria, Czechia, Cameroon, Taiwan, Province of China, Morocco
Lipofectamine 2000 is a cationic lipid-based transfection reagent designed for efficient and reliable delivery of nucleic acids, such as plasmid DNA and small interfering RNA (siRNA), into a wide range of eukaryotic cell types. It facilitates the formation of complexes between the nucleic acid and the lipid components, which can then be introduced into cells to enable gene expression or gene silencing studies.
Sourced in United States, United Kingdom
Endo Hf is a type II restriction enzyme produced by New England Biolabs. It recognizes and cleaves the DNA sequence 5'-CGGT-3' and its reverse complement 5'-CCGC-3'.
Sourced in United States, Germany, United Kingdom, China, Japan, France, Switzerland, Sweden, Italy, Netherlands, Spain, Canada, Brazil, Australia, Macao
Trypsin is a serine protease enzyme that is commonly used in cell culture and molecular biology applications. It functions by cleaving peptide bonds at the carboxyl side of arginine and lysine residues, which facilitates the dissociation of adherent cells from cell culture surfaces and the digestion of proteins.

More about "Protein Glycosylation"

protein glycosylation, glycan, sugar chains, endoplasmic reticulum, Golgi apparatus, eukaryotic cells, post-translational modification, protein stability, solubility, folding, trafficking, biological activity, glycosylation patterns, biomarkers, disease, glycan structures, protein function, therapeutic glycoproteins, PNGase F, Endo H, N-linked glycosylation, O-linked glycans, Tunicamycin, O-glycosidase, glycoprotein staining, GeneArt, Lipofectamine 2000, Endo Hf, Trypsin, PubCompare.ai, protocols, reproducibility, accuracy